Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...

reported in the New England Journal of Medicine that patients with COPD and type 2 inflammation who received the biologic agent dupilumab had fewer exacerbations, better lung function, and less severe ...

After a long road that included a three-month delay as the agency pushed for additional data, the US FDA has approved Sanofi and Regeneron's Dupixent (dupilumab) for COPD - as has China's National ...

Chronic obstructive pulmonary disease (COPD ... to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor Dupixent (dupilumab) as a treatment for the progressive lung disease, shortly after ...

Reuters Health Information, March 07, 2024 Dupilumab Earns FDA Priority Review for Add-On COPD Care The first new COPD treatment in a decade showed safety and effectiveness in a subset of patients ...